FDA approved gilteritinib, a targeted drug for leukemia tested at UPenn
On Nov. 28, 2018, The U.S. Food and Drug Administration (FDA) announced it had approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.
Patients with these mutations who have relapsed or refractory AML have very low response rates to chemotherapy at the time of relapse and their survival is poor as a result.
Tags:
Source: Penn Medicine
Credit: Photo: Microscopy of acute leukemia in bone_marrow, courtesy American Society of Hematology.
